Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Activated T-cells inhibit neurogenesis by releasing granzyme B: rescue by Kv1.3 blockers.

Wang T, Lee MH, Johnson T, Allie R, Hu L, Calabresi PA, Nath A.

J Neurosci. 2010 Apr 7;30(14):5020-7. doi: 10.1523/JNEUROSCI.0311-10.2010.

2.

Blockade of Kv1.3 potassium channels inhibits differentiation and granzyme B secretion of human CD8+ T effector memory lymphocytes.

Hu L, Wang T, Gocke AR, Nath A, Zhang H, Margolick JB, Whartenby KA, Calabresi PA.

PLoS One. 2013;8(1):e54267. doi: 10.1371/journal.pone.0054267.

3.

Granzyme B-induced neurotoxicity is mediated via activation of PAR-1 receptor and Kv1.3 channel.

Wang T, Lee MH, Choi E, Pardo-Villamizar CA, Lee SB, Yang IH, Calabresi PA, Nath A.

PLoS One. 2012;7(8):e43950. doi: 10.1371/journal.pone.0043950.

4.

Psora-4, a Kv1.3 Blocker, Enhances Differentiation and Maturation in Neural Progenitor Cells.

Zhou YY, Hou GQ, He SW, Xiao Z, Xu HJ, Qiu YT, Jiang S, Zheng H, Li ZY.

CNS Neurosci Ther. 2015 Jul;21(7):558-67. doi: 10.1111/cns.12402.

PMID:
25976092
5.

Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes.

Hu L, Pennington M, Jiang Q, Whartenby KA, Calabresi PA.

J Immunol. 2007 Oct 1;179(7):4563-70.

6.

Kv1.3 blockers ameliorate allergic contact dermatitis by preferentially suppressing effector memory T cells in a rat model.

Ueyama A, Imura K, Kasai-Yamamoto E, Tai N, Nagira M, Shichijo M, Yasui K.

Clin Exp Dermatol. 2013 Dec;38(8):897-903. doi: 10.1111/ced.12097.

PMID:
24252082
7.

Selective blockage of Kv1.3 and Kv3.1 channels increases neural progenitor cell proliferation.

Liebau S, Pröpper C, Böckers T, Lehmann-Horn F, Storch A, Grissmer S, Wittekindt OH.

J Neurochem. 2006 Oct;99(2):426-37.

8.

Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation.

Beeton C, Barbaria J, Giraud P, Devaux J, Benoliel AM, Gola M, Sabatier JM, Bernard D, Crest M, Béraud E.

J Immunol. 2001 Jan 15;166(2):936-44.

9.

Acacetin blocks kv1.3 channels and inhibits human T cell activation.

Zhao N, Dong Q, Fu XX, Du LL, Cheng X, Du YM, Liao YH.

Cell Physiol Biochem. 2014;34(4):1359-72. doi: 10.1159/000366343.

10.

Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells.

Varga Z, Gurrola-Briones G, Papp F, Rodríguez de la Vega RC, Pedraza-Alva G, Tajhya RB, Gaspar R, Cardenas L, Rosenstein Y, Beeton C, Possani LD, Panyi G.

Mol Pharmacol. 2012 Sep;82(3):372-82. doi: 10.1124/mol.112.078006.

11.

Targeting effector memory T-cells with Kv1.3 blockers.

Wulff H, Pennington M.

Curr Opin Drug Discov Devel. 2007 Jul;10(4):438-45. Review.

PMID:
17659485
12.

Immunosuppressive evidence of Tityus serrulatus toxins Ts6 and Ts15: insights of a novel K(+) channel pattern in T cells.

Pucca MB, Bertolini TB, Cerni FA, Bordon KC, Peigneur S, Tytgat J, Bonato VL, Arantes EC.

Immunology. 2016 Feb;147(2):240-50. doi: 10.1111/imm.12559.

PMID:
26595158
13.

Effects of various K+ channel blockers on spontaneous glycine release at rat spinal neurons.

Shoudai K, Nonaka K, Maeda M, Wang ZM, Jeong HJ, Higashi H, Murayama N, Akaike N.

Brain Res. 2007 Jul 9;1157:11-22.

PMID:
17555723
14.

Different calcium influx characteristics upon Kv1.3 and IKCa1 potassium channel inhibition in T helper subsets.

Orbán C, Bajnok A, Vásárhelyi B, Tulassay T, Toldi G.

Cytometry A. 2014 Jul;85(7):636-41. doi: 10.1002/cyto.a.22479.

15.

Dopamine exerts no acute effects on Kv1.3 in activated encephalitogenic T cells.

Strauss U, Herbrik M, Mix E, Bajorat R, Jung S, Gimsa U, Rolfs A.

Neuroimmunomodulation. 2005;12(1):45-53.

PMID:
15756052
16.

Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840.

Wulff H.

Expert Opin Ther Pat. 2010 Dec;20(12):1759-65. doi: 10.1517/13543776.2010.528392.

17.

The inhibitory effect of copper ions on lymphocyte Kv1.3 potassium channels.

Teisseyre A, Mozrzymas JW.

J Physiol Pharmacol. 2006 Jun;57(2):301-14.

18.

A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone.

Harvey AJ, Baell JB, Toovey N, Homerick D, Wulff H.

J Med Chem. 2006 Feb 23;49(4):1433-41.

PMID:
16480279
19.

Lymphocyte calcium influx characteristics and their modulation by Kv1.3 and IKCa1 channel inhibitors in healthy pregnancy and preeclampsia.

Toldi G, Stenczer B, Treszl A, Kollár S, Molvarec A, Tulassay T, Rigó J, Vásárhelyi B.

Am J Reprod Immunol. 2011 Feb;65(2):154-63. doi: 10.1111/j.1600-0897.2010.00899.x.

PMID:
20649894
20.

Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.

Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, Khaytin I, Calabresi PA, Chen CY, Gutman GA, Chandy KG.

Mol Pharmacol. 2005 Apr;67(4):1369-81.

Items per page

Supplemental Content

Support Center